Hutchison China Meditech News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.11.24	HUTCHMED To Receive Milestone Payment As Takeda Launches FRUZAQLA For Colorectal Cancer In Japan (RTTNews)
30.08.24	HUTCHMED Withdraws SNDA For Fruquintinib And Paclitaxel Combination In Second-Line Gastric Cancer (RTTNews)
04.07.24	HUTCHMED Announces NDA Acceptance For Tazemetostat In China - Quick Facts (RTTNews)
02.04.24	HUTCHMED (China) And Innovent's Endometrial Cancer Treatment Granted Priority Review By NMPA (RTTNews)
28.02.24	HUTCHMED Turns To Profit In FY23, Revenue Surges; Stock Up In Pre-market (RTTNews)
30.01.24	HUTCHMED Announces Marketing Approval For ELUNATE By Pharmacy And Poisons Board Of Hong Kong (RTTNews)
21.08.23	HUTCHMED : Sovleplenib Phase III ESLIM-01 Study Meets Main Goal In Primary Immune Thrombocytopenia (RTTNews)
23.01.23	Takeda To Pay Up To $1.13 Bln To HUTCHMED For Exclusive License Of Fruquintinib Outside China (RTTNews)
19.12.22	HUTCHMED Initiates Rolling Submission Of NDA To FDA For Fruquintinib To Treat Refractory CRC (RTTNews)
14.11.22	HUTCHMED Reports Mixed Results In Fruquintinib PhaseIII Study In Second-Line Gastric Cancer In China (RTTNews)
08.08.22	HUTCHMED Stock Up As Fruquintinib Global Phase III FRESCO-2 Study In CRC Meets Primary Goal (RTTNews)
06.07.22	HUTCHMED, Inmagene: First Atopic Dermatitis Patient Dosed In Global Phase I Trial Of IMG-007 (RTTNews)
16.05.22	Inmagene Obtains FDA IND Clearance For BTK Inhibitor Targeting Immunological Diseases (RTTNews)
02.05.22	HUTCHMED Receives CRL From FDA For Surufatinib To Treat Advanced Neuroendocrine Tumors (RTTNews)
28.03.22	Biotech Stocks Facing FDA Decision In April 2022 (RTTNews)
24.11.21	HUTCHMED, AstraZeneca Initiate Phase III Trial Of ORPATHYS& TAGRISSO In Certain Lung Cancer Patients (RTTNews)
08.09.21	Hutchmed Says First Patient Dosed In China Phase III Trial Of Orpathys And Tagrisso In Lung Cancer (RTTNews)
09.08.21	Epizyme, Hutchmed Collaborate To Develop And Commercialize Tazverik In Greater China (RTTNews)
21.06.21	HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors (PR Newswire)
11.01.21	Chi-Med, Inmagene To Develop & Commercialize Portfolio Of Drug Candidates For Immunological Diseases (RTTNews)
15.11.18	IMMY Turning Heads, HSM Awaits Phase 3 Data This Year, LQDA On Watch (RTTNews)
16.03.18	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 21st and 22nd, 2018 (PR Newswire)
16.03.18	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 21st and 22nd, 2018 (PR Newswire)
12.10.17	Government of Canada promotes innovation for economic growth and jobs in British Columbia and Canada (PR Newswire)
10.10.17	Meridian Mining Announces Q3 Manganese Production & Sales (PR Newswire)
16.03.17	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 22nd and 23rd, 2017 (PR Newswire)
21.11.16	Chi-Med webcast presentation now available for on-demand viewing: Deutsche Bank ADR Virtual Investor Conference (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Hutchison China Meditech Ltd (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten